FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer
| | | | | |

FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer

On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence
| | | | | |

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence

In 2006, the National Cancer Institute (NCI) launched the TAILORx trial to determine whether gene expression patterns in…

NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
| | | | |

NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence

On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…